Lead Product(s): Denosumab
Therapeutic Area: Endocrinology
Highest Development Status: Approved Product Type: Large molecule
Deal Size: $2,800.0 million Upfront Cash: $2,800.0 million
Deal Type: Collaboration January 02, 2020
The stratagic collaboration between Amgen and BeiGene will significantly accelerate Amgen's plans to expand its oncology presence in China.